Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Mangoceuticals, Inc. ( (MGRX) ) is now available.
On November 13, 2025, Mangoceuticals, Inc. clarified its earlier announcement regarding the launch of its weight-management programs, MangoRx Direct and PeachesRx Direct. These programs are licensed to issue prescriptions for FDA-approved GLP-1 medications from Eli Lilly and Novo Nordisk, providing patients access to these medications through Mangoceuticals’ platform. The programs offer telehealth consultations and personalized care plans, enhancing the company’s position in the telemedicine and weight management industry.
More about Mangoceuticals, Inc.
Mangoceuticals, Inc. is focused on developing men’s health and wellness products and services through a telemedicine platform. The company targets the growing sector of men’s wellness, particularly in areas such as erectile dysfunction, hair growth, hormone replacement therapies, and weight management.
Average Trading Volume: 1,301,207
Technical Sentiment Signal: Sell
Current Market Cap: $18.54M
For detailed information about MGRX stock, go to TipRanks’ Stock Analysis page.